Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ENERGY 3 Study
NCT06046820Phase 3Terminated
- Sponsor
- Inozyme Pharma
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of INZ-701 in ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency, sponsored by Inozyme Pharma. Started Nov 2023; status: terminated.
02
Drugs
INZ-701
03
Conditions
ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
Beyond the preview
Go deeper on NCT06046820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046820.